Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 15.148
Filtrer
1.
Lasers Med Sci ; 39(1): 171, 2024 Jul 05.
Article de Anglais | MEDLINE | ID: mdl-38965082

RÉSUMÉ

To evaluate the effects of red and infrared wavelengths, separately and combined, on the inflammatory process and collagen deposition in muscle damage caused by B. leucurus venom. 112 mice were inoculated with diluted venom (0.6mg/kg) in the gastrocnemius muscle. The animals were divided into four groups: one control (CG) and three treatments, namely: 1) red laser (λ=660 nm) (RG), 2) infrared laser (λ=808 nm) (IG) and 3) red laser (λ=660 nm) + infrared (λ=808 nm) (RIG). Each group was subdivided into four subgroups, according to the duration of treatment application (applications every 24 hours over evaluation times of up to 144 hours). A diode laser was used (0.1 W, CW, 1J/point, ED: 10 J/cm2). Both wavelengths reduced the intensity of inflammation and the combination between them significantly intensified the anti-inflammatory response. Photobiomodulation also changed the type of inflammatory infiltrate observed and RIG had the highest percentage of mononuclear cells in relation to the other groups. Hemorrhage intensity was significantly lower in treated animals and RIG had the highest number of individuals in which this variable was classified as mild. As for collagen deposition, there was a significant increase in RG in relation to CG, in RIG in relation to CG and in RIG in relation to IG. Photobiomodulation proved to be effective in the treatment of inflammation and hemorrhage caused by B. leucurus venom and stimulated collagen deposition. Better results were obtained with the combined wavelengths.


Sujet(s)
Bothrops , Collagène , Venins de crotalidé , Hémorragie , Inflammation , Photothérapie de faible intensité , Muscles squelettiques , Animaux , Souris , Photothérapie de faible intensité/méthodes , Muscles squelettiques/effets des radiations , Muscles squelettiques/effets des médicaments et des substances chimiques , Hémorragie/anatomopathologie , Collagène/métabolisme , Collagène/analyse , Venins de crotalidé/toxicité , Rayons infrarouges , Mâle , Lasers à semiconducteur/usage thérapeutique , Morsures de serpent/radiothérapie
2.
J Proteome Res ; 23(7): 2452-2473, 2024 Jul 05.
Article de Anglais | MEDLINE | ID: mdl-38965921

RÉSUMÉ

Cancer cachexia is an involuntary loss of body weight, mostly of skeletal muscle. Previous research favors the existence of a microbiota-muscle crosstalk, so the aim of the study was to evaluate the impact of microbiota alterations induced by antibiotics on skeletal muscle proteins expression. Skeletal muscle proteome changes were investigated in control (CT) or C26 cachectic mice (C26) with or without antibiotic treatment (CT-ATB or C26-ATB, n = 8 per group). Muscle protein extracts were divided into a sarcoplasmic and myofibrillar fraction and then underwent label-free liquid chromatography separation, mass spectrometry analysis, Mascot protein identification, and METASCAPE platform data analysis. In C26 mice, the atrogen mafbx expression was 353% higher than CT mice and 42.3% higher than C26-ATB mice. No effect on the muscle protein synthesis was observed. Proteomic analyses revealed a strong effect of antibiotics on skeletal muscle proteome outside of cachexia, with adaptative processes involved in protein folding, growth, energy metabolism, and muscle contraction. In C26-ATB mice, proteome adaptations observed in CT-ATB mice were blunted. Differentially expressed proteins were involved in other processes like glucose metabolism, oxidative stress response, and proteolysis. This study confirms the existence of a microbiota-muscle axis, with a muscle response after antibiotics that varies depending on whether cachexia is present.


Sujet(s)
Antibactériens , Cachexie , Muscles squelettiques , Protéome , Cachexie/métabolisme , Cachexie/microbiologie , Animaux , Muscles squelettiques/métabolisme , Muscles squelettiques/effets des médicaments et des substances chimiques , Antibactériens/pharmacologie , Antibactériens/effets indésirables , Protéome/métabolisme , Protéome/analyse , Souris , Tumeurs/métabolisme , Tumeurs/complications , Tumeurs/traitement médicamenteux , Protéines du muscle/métabolisme , Mâle , Protéomique/méthodes , Microbiote/effets des médicaments et des substances chimiques , Métabolisme énergétique/effets des médicaments et des substances chimiques
3.
J Biochem Mol Toxicol ; 38(7): e23750, 2024 Jul.
Article de Anglais | MEDLINE | ID: mdl-38952032

RÉSUMÉ

The treatment of organophosphate (OP) anticholinesterases currently lacks an effective oxime reactivator of OP-inhibited acetylcholinesterase (AChE) which can penetrate the blood-brain barrier (BBB). Our laboratories have synthesized novel substituted phenoxyalkyl pyridinium oximes and tested them for their ability to promote survival of rats challenged with lethal doses of nerve agent surrogates. These previous studies demonstrated the ability of some of these oximes to promote 24-h survival to rats challenged with a lethal level of highly relevant surrogates for sarin and VX. The reactivation of OP-inhibited AChE in peripheral tissues was likely to be a major contributor to their efficacy in survival of lethal OP challenges. In the present study, twenty of these novel oximes were screened in vitro for reactivation ability for AChE in rat skeletal muscle and serum using two nerve agent surrogates: phthalimidyl isopropyl methylphosphonate (PIMP, a sarin surrogate) and 4-nitrophenyl ethyl methylphosphonate (NEMP, a VX surrogate). The oximes demonstrated a range of 23%-102% reactivation of AChE in vitro across both tissue types. Some of the novel oximes tested in the present study demonstrated the ability to more effectively reactivate AChE in serum than the currently approved oxime, 2-PAM. Therefore, some of these novel oximes have the potential to reverse AChE inhibition in peripheral target tissues and contribute to survival efficacy.


Sujet(s)
Acetylcholinesterase , Anticholinestérasiques , Réactivateurs de la cholinestérase , Muscles squelettiques , Organophosphates , Oximes , Animaux , Oximes/pharmacologie , Oximes/composition chimique , Rats , Acetylcholinesterase/métabolisme , Acetylcholinesterase/sang , Muscles squelettiques/effets des médicaments et des substances chimiques , Muscles squelettiques/enzymologie , Anticholinestérasiques/pharmacologie , Anticholinestérasiques/toxicité , Organophosphates/toxicité , Mâle , Réactivateurs de la cholinestérase/pharmacologie , Réactivateurs de la cholinestérase/composition chimique , Composés de pyridinium/pharmacologie , Rat Sprague-Dawley
4.
Cell Death Dis ; 15(7): 470, 2024 Jul 02.
Article de Anglais | MEDLINE | ID: mdl-38956034

RÉSUMÉ

The present study aims to develop and characterize a controlled-release delivery system for protein therapeutics in skeletal muscle regeneration following an acute injury. The therapeutic protein, a membrane-GPI anchored protein called Cripto, was immobilized in an injectable hydrogel delivery vehicle for local administration and sustained release. The hydrogel was made of poly(ethylene glycol)-fibrinogen (PEG-Fibrinogen, PF), in the form of injectable microspheres. The PF microspheres exhibited a spherical morphology with an average diameter of approximately 100 micrometers, and the Cripto protein was uniformly entrapped within them. The release rate of Cripto from the PF microspheres was controlled by tuning the crosslinking density of the hydrogel, which was varied by changing the concentration of poly(ethylene glycol) diacrylate (PEG-DA) crosslinker. In vitro experiments confirmed a sustained-release profile of Cripto from the PF microspheres for up to 27 days. The released Cripto was biologically active and promoted the in vitro proliferation of mouse myoblasts. The therapeutic effect of PF-mediated delivery of Cripto in vivo was tested in a cardiotoxin (CTX)-induced muscle injury model in mice. The Cripto caused an increase in the in vivo expression of the myogenic markers Pax7, the differentiation makers eMHC and Desmin, higher numbers of centro-nucleated myofibers and greater areas of regenerated muscle tissue. Collectively, these results establish the PF microspheres as a potential delivery system for the localized, sustained release of therapeutic proteins toward the accelerated repair of damaged muscle tissue following acute injuries.


Sujet(s)
Préparations à action retardée , Muscles squelettiques , Polyéthylène glycols , Animaux , Muscles squelettiques/métabolisme , Muscles squelettiques/traumatismes , Muscles squelettiques/effets des médicaments et des substances chimiques , Souris , Polyéthylène glycols/composition chimique , Microsphères , Fibrinogène/métabolisme , Hydrogels/composition chimique , Régénération/effets des médicaments et des substances chimiques , Myoblastes/métabolisme , Myoblastes/effets des médicaments et des substances chimiques , Humains , Prolifération cellulaire/effets des médicaments et des substances chimiques , Facteur de transcription PAX7/métabolisme , Mâle , Souris de lignée C57BL , Maladies musculaires/traitement médicamenteux , Maladies musculaires/anatomopathologie , Maladies musculaires/métabolisme
5.
Sci Rep ; 14(1): 15554, 2024 Jul 05.
Article de Anglais | MEDLINE | ID: mdl-38969654

RÉSUMÉ

Human hallmarks of sarcopenia include muscle weakness and a blunted response to exercise. Nicotinamide N-methyltransferase inhibitors (NNMTis) increase strength and promote the regenerative capacity of aged muscle, thus offering a promising treatment for sarcopenia. Since human hallmarks of sarcopenia are recapitulated in aged (24-month-old) mice, we treated mice from 22 to 24 months of age with NNMTi, intensive exercise, or a combination of both, and compared skeletal muscle adaptations, including grip strength, longitudinal running capacity, plantarflexor peak torque, fatigue, and muscle mass, fiber type, cross-sectional area, and intramyocellular lipid (IMCL) content. Exhaustive proteome and metabolome analyses were completed to identify the molecular mechanisms underlying the measured changes in skeletal muscle pathophysiology. Remarkably, NNMTi-treated aged sedentary mice showed ~ 40% greater grip strength than sedentary controls, while aged exercised mice only showed a 20% increase relative to controls. Importantly, the grip strength improvements resulting from NNMTi treatment and exercise were additive, with NNMTi-treated exercised mice developing a 60% increase in grip strength relative to sedentary controls. NNMTi treatment also promoted quantifiable improvements in IMCL content and, in combination with exercise, significantly increased gastrocnemius fiber CSA. Detailed skeletal muscle proteome and metabolome analyses revealed unique molecular mechanisms associated with NNMTi treatment and distinct molecular mechanisms and cellular processes arising from a combination of NNMTi and exercise relative to those given a single intervention. These studies suggest that NNMTi-based drugs, either alone or combined with exercise, will be beneficial in treating sarcopenia and a wide range of age-related myopathies.


Sujet(s)
Vieillissement , Muscles squelettiques , Nicotinamide N-methyltransferase , Conditionnement physique d'animal , Sarcopénie , Animaux , Nicotinamide N-methyltransferase/métabolisme , Muscles squelettiques/métabolisme , Muscles squelettiques/effets des médicaments et des substances chimiques , Souris , Vieillissement/physiologie , Sarcopénie/métabolisme , Sarcopénie/traitement médicamenteux , Mâle , Force musculaire/effets des médicaments et des substances chimiques , Souris de lignée C57BL , Antienzymes/pharmacologie
6.
Nutrients ; 16(13)2024 Jun 25.
Article de Anglais | MEDLINE | ID: mdl-38999759

RÉSUMÉ

The study aimed to show the potential clinical application of supplements used among sportsmen for patients suffering from Intensive Care Unit-acquired Weakness (ICUAW) treatment. ICUAW is a common complication affecting approximately 40% of critically ill patients, often leading to long-term functional disability. ICUAW comprises critical illness polyneuropathy, critical illness myopathy, or a combination of both, such as critical illness polyneuromyopathy. Muscle degeneration begins shortly after the initiation of mechanical ventilation and persists post-ICU discharge until proteolysis and autophagy processes normalize. Several factors, including prolonged bedrest and muscle electrical silencing, contribute to muscle weakness, resulting from an imbalance between protein degradation and synthesis. ICUAW is associated with tissue hypoxia, oxidative stress, insulin resistance, reduced glucose uptake, lower adenosine triphosphate (ATP) formation, mitochondrial dysfunction, and increased free-radical production. Several well-studied dietary supplements and pharmaceuticals commonly used by athletes are proven to prevent the aforementioned mechanisms or aid in muscle building, regeneration, and maintenance. While there is no standardized treatment to prevent the occurrence of ICUAW, nutritional interventions have demonstrated the potential for its mitigation. The use of ergogenic substances, popular among muscle-building sociates, may offer potential benefits in preventing muscle loss and aiding recovery based on their work mechanisms.


Sujet(s)
Maladie grave , Compléments alimentaires , Unités de soins intensifs , Faiblesse musculaire , Humains , Maladie grave/thérapie , Anabolisants/usage thérapeutique , Muscles squelettiques/effets des médicaments et des substances chimiques , Muscles squelettiques/métabolisme , Polyneuropathies/traitement médicamenteux
7.
Nutrients ; 16(13)2024 Jul 03.
Article de Anglais | MEDLINE | ID: mdl-38999874

RÉSUMÉ

A useful perioperative nutritional therapy for highly invasive esophageal cancer surgical cases needs to be developed. We clarified the usefulness of amino-acid-enriched nutritional therapy using glutamine (Gln)/arginine (Arg)/calcium ß-hydroxy-ß-methylbutyrate (HMB) products on the short-term postoperative outcomes of minimally invasive esophagectomy for esophageal cancer. Altogether, 114 patients (Gln/Arg/HMB group) received perioperative nutritional therapy with Gln/Arg/HMB products, and we retrospectively investigated the change in nutritional parameters including skeletal muscle mass, occurrence of postoperative complications, and short-term postoperative outcomes in this group. The results were compared between the Gln/Arg/HMB and control groups (79 patients not receiving the Gln/Arg/HMB products). The incidence of all postoperative complications, sputum expectoration disorder, and pleural effusion of grade ≥ III was significantly lower in the Gln/Arg/HMB group (62.0% vs. 38.6%, p = 0.001; 44.3% vs. 28.1%, p = 0.020; 27.8% vs. 13.2%, p = 0.011, respectively). The psoas muscle area and postoperative body weight were significantly higher at 1 month and 1 year after surgery in the Gln/Arg/HMB group than in the control group (93.5% vs. 99.9%, p < 0.001; 92.0% vs. 95.4%, p = 0.006). Perioperative amino-acid-enriched nutritional therapy may improve the short-term postoperative outcomes, nutritional status, and skeletal muscle mass of esophageal cancer surgical patients.


Sujet(s)
Arginine , Tumeurs de l'oesophage , Oesophagectomie , Glutamine , Soins périopératoires , Complications postopératoires , Valérates , Humains , Mâle , Tumeurs de l'oesophage/chirurgie , Femelle , Arginine/administration et posologie , Études rétrospectives , Sujet âgé , Adulte d'âge moyen , Valérates/administration et posologie , Complications postopératoires/prévention et contrôle , Glutamine/administration et posologie , Soins périopératoires/méthodes , Calcium , Thérapie nutritionnelle/méthodes , Résultat thérapeutique , État nutritionnel , Muscles squelettiques/effets des médicaments et des substances chimiques
8.
Int J Mol Sci ; 25(13)2024 Jun 26.
Article de Anglais | MEDLINE | ID: mdl-39000102

RÉSUMÉ

Aberrant expression of the double homeobox 4 (DUX4) gene in skeletal muscle predominantly drives the pathogenesis of facioscapulohumeral muscular dystrophy (FSHD). We recently demonstrated that berberine, an herbal extract known for its ability to stabilize guanine-quadruplex structures, effectively downregulates DUX4 expression in FSHD patient-derived myoblasts and in mice overexpressing exogenous DUX4 after viral vector-based treatment. Here, we sought to confirm berberine's inhibitory efficacy on DUX4 in the widely used FSHD-like transgenic mouse model, ACTA1-MCM/FLExDUX4, where DUX4 is induced at pathogenic levels using tamoxifen. Animals repeatedly treated with berberine via intraperitoneal injections for 4 weeks exhibited significant reductions in both mRNA and protein levels of DUX4, and in mRNA expression of murine DUX4-related genes. This inhibition translated into improved forelimb muscle strength and positive alterations in important FSHD-relevant cellular pathways, although its impact on muscle mass and histopathology was less pronounced. Collectively, our data confirm the efficacy of berberine in downregulating DUX4 expression in the most relevant FSHD mouse model. However, further optimization of dosing regimens and new studies to enhance the bioavailability of berberine in skeletal muscle are warranted to fully leverage its therapeutic potential for FSHD treatment.


Sujet(s)
Berbérine , Modèles animaux de maladie humaine , Protéines à homéodomaine , Souris transgéniques , Muscles squelettiques , Dystrophie musculaire facio-scapulo-humérale , Animaux , Dystrophie musculaire facio-scapulo-humérale/traitement médicamenteux , Dystrophie musculaire facio-scapulo-humérale/métabolisme , Dystrophie musculaire facio-scapulo-humérale/génétique , Dystrophie musculaire facio-scapulo-humérale/anatomopathologie , Protéines à homéodomaine/génétique , Protéines à homéodomaine/métabolisme , Souris , Muscles squelettiques/métabolisme , Muscles squelettiques/effets des médicaments et des substances chimiques , Berbérine/pharmacologie , Actines/métabolisme , Actines/génétique , Humains
9.
Int J Mol Sci ; 25(13)2024 Jul 08.
Article de Anglais | MEDLINE | ID: mdl-39000606

RÉSUMÉ

Sarcopenia refers to an age-related decrease in muscle mass and strength. The gut-muscle axis has been proposed as a promising target to alleviate muscle atrophy. The effect of KL-Biome-a postbiotic preparation comprising heat-killed Lactiplantibacillus plantarum KM-2, its metabolites, and an excipient (soybean powder)-on muscle atrophy was evaluated using dexamethasone (DEX)-induced atrophic C2C12 myoblasts and C57BL/6J mice. KL-Biome significantly downregulated the expression of genes (Atrogin-1 and MuRF1) associated with skeletal muscle degradation but increased the anabolic phosphorylation of FoxO3a, Akt, and mTOR in C2C12 cells. Oral administration of KL-Biome (900 mg/kg) for 8 weeks significantly improved muscle mass, muscle function, and serum lactate dehydrogenase levels in DEX-treated mice. KL-Biome administration increased gut microbiome diversity and reversed DEX-mediated gut microbiota alterations. Furthermore, it significantly increased the relative abundances of the genera Subdologranulum, Alistipes, and Faecalibacterium prausnitzii, which are substantially involved in short-chain fatty acid production. These findings suggest that KL-Biome exerts beneficial effects on muscle atrophy by regulating gut microbiota.


Sujet(s)
Dexaméthasone , Microbiome gastro-intestinal , Souris de lignée C57BL , Muscles squelettiques , Amyotrophie , Animaux , Amyotrophie/traitement médicamenteux , Amyotrophie/métabolisme , Amyotrophie/induit chimiquement , Souris , Dexaméthasone/pharmacologie , Dexaméthasone/effets indésirables , Microbiome gastro-intestinal/effets des médicaments et des substances chimiques , Muscles squelettiques/effets des médicaments et des substances chimiques , Muscles squelettiques/métabolisme , Muscles squelettiques/anatomopathologie , Mâle , Protéines du muscle/métabolisme , Protéines du muscle/génétique , Protéine O3 à motif en tête de fourche/métabolisme , Protéine O3 à motif en tête de fourche/génétique , Ubiquitin-protein ligases/métabolisme , Ubiquitin-protein ligases/génétique , SKP cullin F-box protein ligases/métabolisme , SKP cullin F-box protein ligases/génétique , Probiotiques/administration et posologie , Protéines à motif tripartite/métabolisme , Protéines à motif tripartite/génétique , Sarcopénie/traitement médicamenteux , Sarcopénie/métabolisme , Sarcopénie/anatomopathologie , Sérine-thréonine kinases TOR/métabolisme , Protéines proto-oncogènes c-akt/métabolisme , Lignée cellulaire , Lactobacillus plantarum
10.
Arch Biochem Biophys ; 758: 110083, 2024 Aug.
Article de Anglais | MEDLINE | ID: mdl-38969196

RÉSUMÉ

Fibromyalgia (FMS) is a persistent syndrome marked by widespread musculoskeletal pain and behavioural symptoms. Given the hypothesis linking FMS aetiology to mitochondrial dysfunction and oxidative stress, we examined the biochemical correlation among these factors by studying specific proteins associated with mitochondrial homeostasis in muscle. Additionally, this study investigated the role of Boswellia serrata gum resin extract (BS), known for its various functions, including the potent induction of antioxidant enzymes, in determining protective or reparative mechanisms in the muscle cells. Sprague-Dawley rats were injected with reserpine to induce FMS. These animals exhibited moderate changes in hind limb skeletal muscles, experiencing mobility difficulties. Additionally, there were noteworthy morphological and ultrastructural alterations, along with the expression of myogenin, mitochondrial enzymes and oxidative stress markers in the gastrocnemius muscle. Interestingly, BS demonstrated a reduction in spontaneous motor activity difficulties. Moreover, BS showed a positive impact on musculoskeletal morphostructural aspects, as well as a decrease in oxidative stress and mitochondrial alterations. In particular, BS restored the mRNA expression of citrate synthase and cytochrome-c oxidase subunit II and the activity of electron transfer chain complexes. BS also influenced mitochondrial biogenesis, upregulating PGC-1α expression and the related transcription factors (Nrf1, Tfam, Nrf2, FOXO3a, SIRT3, GCLC, NQO1, SOD2 and GPx4), oxidative stress (lipid peroxidation, GSH levels and GSH-Px activity) and mitochondrial dynamics and function (Mnf2 expression and CoQ10 levels). Overall, this study underlined the key role of the mitochondrial alteration in FMS and that BS had a very high antioxidant effect in these organelles and also in the cells.


Sujet(s)
Fibromyalgie , Muscles squelettiques , Stress oxydatif , Rat Sprague-Dawley , Fibromyalgie/métabolisme , Fibromyalgie/induit chimiquement , Fibromyalgie/anatomopathologie , Animaux , Muscles squelettiques/métabolisme , Muscles squelettiques/effets des médicaments et des substances chimiques , Muscles squelettiques/anatomopathologie , Rats , Stress oxydatif/effets des médicaments et des substances chimiques , Extraits de plantes/pharmacologie , Mitochondries du muscle/métabolisme , Mitochondries du muscle/effets des médicaments et des substances chimiques , Mitochondries du muscle/anatomopathologie , Mâle , Mitochondries/métabolisme , Mitochondries/effets des médicaments et des substances chimiques , Antioxydants/métabolisme
11.
Nutrients ; 16(13)2024 Jun 27.
Article de Anglais | MEDLINE | ID: mdl-38999792

RÉSUMÉ

Omega-3 is a family of n-3 polyunsaturated fatty acids (PUFAs), which have been used to treat a wide variety of chronic diseases, due mainly to their antioxidant and anti-inflammatory properties, among others. In this context, omega-3 could be post-exercise recovery agent and sports supplement that could improve performance by preserving and promoting skeletal muscle mass and strength. No conclusive evidence, however, exists about the potential effects of omega-3 on post-exercise biomarkers and sports performance in physically healthy adults. Based on the PRISMA in Exercise, Rehabilitation, Sports Medicine, and Sports Science (PERSiST) guidelines, we systematically reviewed studies indexed in Web of Science, Scopus, and Medline to assess the effects of omega-3 on post-exercise inflammation, muscle damage, oxidant response, and sports performance in physically healthy adults. The search was performed on original articles published in the last 10 years up to 5 May 2024, with a controlled trial design in which omega-3 supplementation was compared with a control group. Among 14,971 records identified in the search, 13 studies met the selection criteria. The duration of the interventions ranged from 1 day to 26 weeks of supplementation and the doses used were heterogeneous. Creatine kinase (CK) and lactate dehydrogenase (LDH) were significantly higher (p < 0.05) in the control group in 3 of the 4 studies where these markers were analyzed. C-reactive protein (CRP) was significantly higher (p < 0.05) in the control group of 2 of the 13 studies where this marker was analyzed. The delayed onset muscle soreness (DOMS) gave mixed results. Interleukin 6 (IL-6) showed improvements with supplementation, but tumor necrosis factor-α (TNF-α) displayed no differences. The consumption of n-3 PUFAs improved some indicators of oxidative stress such as reduced glutathione (GSH)/oxidized glutathione (GSSG) ratio. Additional evidence is needed to establish clear recommendations regarding the dose and length of n-3 PUFA supplements. These may benefit the post-exercise inflammatory response, mitigate muscle damage, and decrease oxidative stress caused by exercise. However, studies did not evaluate omega-3 status at baseline or following supplementation and therefore the observations must be treated with caution.


Sujet(s)
Performance sportive , Compléments alimentaires , Exercice physique , Acides gras omega-3 , Inflammation , Muscles squelettiques , Stress oxydatif , Adulte , Femelle , Humains , Mâle , Antioxydants/administration et posologie , Performance sportive/physiologie , Marqueurs biologiques/sang , Creatine kinase/sang , Acides gras omega-3/administration et posologie , Muscles squelettiques/effets des médicaments et des substances chimiques , Muscles squelettiques/métabolisme , Stress oxydatif/effets des médicaments et des substances chimiques , Essais contrôlés randomisés comme sujet
12.
PLoS One ; 19(7): e0299135, 2024.
Article de Anglais | MEDLINE | ID: mdl-39008500

RÉSUMÉ

OBJECTIVES: Meta-analysis was conducted to examine the effect of supplemental curcumin intake on skeletal muscle injury status and to propose an optimal intervention program. METHODS: In accordance with the procedures specified in the PRISMA statement for systematic reviews and meta-analyses of randomized controlled trials, the Review Manager 5.3 was used to analyze the results of creatine kinase (CK), muscle soreness, interleukin-6 (IL-6), and range of motion (ROM) as outcome indicators in the 349 subjects included in the 14 articles. RESULTS: The effect size of curcumin supplementation on muscle soreness, mean difference (MD) = -0.61; the relationship between curcumin supplementation and muscle soreness for time of measurement (I2 = 83.6%)、the relationship between curcumin supplementation and muscle soreness for period of intervention (I2 = 26.2%)、the relationship between whether one had been trained (I2 = 0%) and supplementation dose (I2 = 0%) were not heterogeneous for the relationship between curcumin supplementation and muscle soreness; The effect size on CK, MD = -137.32; the relationship between curcumin supplementation and CK (I2 = 79.7%)、intervention period (I2 = 91.9%)、whether or not trained (I2 = 90.7%)、and no heterogeneity in the relationship between curcumin supplementation and CK for the time of measurement (I2 = 0%); The effect size MD = 4.10 for the effect on ROM; The effect size for IL-6 was MD = -0.33. CONCLUSIONS: This meta-analysis highlights that curcumin supplementation significantly mitigates skeletal muscle damage, with notable improvements in CK levels, muscle soreness, IL-6 levels, and ROM. The results highlight the importance of curcumin dosage and timing, revealing that prolonged supplementation yields the best results, especially for untrained individuals or those less exposed to muscle-damaging exercise. For muscle soreness and ROM enhancement, a pre-emptive, low-dose regimen is beneficial, while immediate post-exercise supplementation is most effective at reducing CK and IL-6 levels.


Sujet(s)
Creatine kinase , Curcumine , Compléments alimentaires , Interleukine-6 , Muscles squelettiques , Myalgie , Curcumine/pharmacologie , Curcumine/administration et posologie , Curcumine/usage thérapeutique , Humains , Muscles squelettiques/effets des médicaments et des substances chimiques , Muscles squelettiques/traumatismes , Muscles squelettiques/métabolisme , Myalgie/traitement médicamenteux , Creatine kinase/sang , Interleukine-6/sang , Interleukine-6/métabolisme , Amplitude articulaire/effets des médicaments et des substances chimiques
13.
J Sports Sci Med ; 23(2): 317-325, 2024 Jun.
Article de Anglais | MEDLINE | ID: mdl-38841630

RÉSUMÉ

People with overweight or obesity preferred high-intensity interval training (HIIT) due to the time-efficiency and pleasure. However, HIIT leads to delayed onset muscle soreness (DOMS). The present study aimed to investigate the effects of omega-3 supplementation on DOMS, muscle damage, and acute inflammatory markers induced by cycling HIIT in untrained males with overweight or obesity. A randomized, double-blinded study was used in the present study. Twenty-four males with a sedentary lifestyle were randomly assigned to either receive omega-3 (O3) (4 g fish oil) or placebo (Con). Subjects consumed the capsules for 4 weeks and performed cycling HIIT at the 4th week. After 4 weeks-intervention, the omega-3 index of O3 group increased by 52.51% compared to the baseline. All subjects performed HIIT at 4th week. The plasma creatine kinase (CK) level of Con group increased throughout 48h after HIIT. While the CK level of O3 group increased only immediately and 24h after HIIT and decreased at 48h after HIIT. The white blood cell count (WBC) of Con group increased immediately after the HIIT, while O3 group did not show such increase. There was no change of CRP in both groups. O3 group had a higher reduction of calf pain score compared to Con group. O3 group also showed a recovery of leg strength faster than Con group. Omega-3 supplementation for 4 weeks lower increased CK level, reduced calf pain score, and recovery leg strength, DOMS markers after cycling HIIT.


Sujet(s)
Cyclisme , Protéine C-réactive , Creatine kinase , Compléments alimentaires , Acides gras omega-3 , Entrainement fractionné de haute intensité , Myalgie , Obésité , Surpoids , Humains , Mâle , Myalgie/prévention et contrôle , Myalgie/étiologie , Myalgie/thérapie , Méthode en double aveugle , Creatine kinase/sang , Acides gras omega-3/administration et posologie , Surpoids/thérapie , Obésité/thérapie , Jeune adulte , Protéine C-réactive/analyse , Protéine C-réactive/métabolisme , Cyclisme/physiologie , Adulte , Numération des leucocytes , Muscles squelettiques/effets des médicaments et des substances chimiques , Marqueurs biologiques/sang , Mode de vie sédentaire
14.
FASEB J ; 38(11): e23718, 2024 Jun 15.
Article de Anglais | MEDLINE | ID: mdl-38847487

RÉSUMÉ

Female carriers of a Duchenne muscular dystrophy (DMD) gene mutation manifest exercise intolerance and metabolic anomalies that may be exacerbated following menopause due to the loss of estrogen, a known regulator of skeletal muscle function and metabolism. Here, we studied the impact of estrogen depletion (via ovariectomy) on exercise tolerance and muscle mitochondrial metabolism in female mdx mice and the potential of estrogen replacement therapy (using estradiol) to protect against functional and metabolic perturbations. We also investigated the effect of estrogen depletion, and replacement, on the skeletal muscle proteome through an untargeted proteomic approach with TMT-labelling. Our study confirms that loss of estrogen in female mdx mice reduces exercise capacity, tricarboxylic acid cycle intermediates, and citrate synthase activity but that these deficits are offset through estrogen replacement therapy. Furthermore, ovariectomy downregulated protein expression of RNA-binding motif factor 20 (Rbm20), a critical regulator of sarcomeric and muscle homeostasis gene splicing, which impacted pathways involving ribosomal and mitochondrial translation. Estrogen replacement modulated Rbm20 protein expression and promoted metabolic processes and the upregulation of proteins involved in mitochondrial dynamics and metabolism. Our data suggest that estrogen mitigates dystrophinopathic features in female mdx mice and that estrogen replacement may be a potential therapy for post-menopausal DMD carriers.


Sujet(s)
Oestrogènes , Souris de lignée mdx , Muscles squelettiques , Protéines de liaison à l'ARN , Animaux , Femelle , Souris , Oestrogènes/métabolisme , Oestrogènes/pharmacologie , Protéines de liaison à l'ARN/métabolisme , Protéines de liaison à l'ARN/génétique , Muscles squelettiques/métabolisme , Muscles squelettiques/effets des médicaments et des substances chimiques , Myopathie de Duchenne/métabolisme , Myopathie de Duchenne/génétique , Souris de lignée C57BL , Ovariectomie , Mitochondries/métabolisme , Mitochondries du muscle/métabolisme , Mitochondries du muscle/effets des médicaments et des substances chimiques
15.
Nutrients ; 16(12)2024 Jun 16.
Article de Anglais | MEDLINE | ID: mdl-38931253

RÉSUMÉ

Advanced glycation end products (AGEs) accumulate in the plasma of pregnant women with hyperglycemia, potentially inducing oxidative stress and fetal developmental abnormalities. Although intrauterine hyperglycemia has been implicated in excessive fetal growth, the effects of maternal AGEs on fetal development remain unclear. We evaluated the differentiation regulators and cellular signaling in the skeletal muscles of infants born to control mothers (ICM), diabetic mothers (IDM), and diabetic mothers supplemented with either cis-palmitoleic acid (CPA) or trans-palmitoleic acid (TPA). Cell viability, reactive oxygen species levels, and myotube formation were assessed in AGE-exposed C2C12 cells to explore potential mitigation by CPA and TPA. Elevated receptors for AGE expression and decreased Akt and AMPK phosphorylation were evident in rat skeletal muscles in IDM. Maternal palmitoleic acid supplementation alleviated insulin resistance by downregulating RAGE expression and enhancing Akt phosphorylation. The exposure of the C2C12 cells to AGEs reduced cell viability and myotube formation and elevated reactive oxygen species levels, which were attenuated by CPA or TPA supplementation. This suggests that maternal hyperglycemia and plasma AGEs may contribute to skeletal muscle disorders in offspring, which are mitigated by palmitoleic acid supplementation. Hence, the maternal intake of palmitoleic acid during pregnancy may have implications for fetal health.


Sujet(s)
Acides gras monoinsaturés , Produits terminaux de glycation avancée , Muscles squelettiques , Espèces réactives de l'oxygène , Récepteur spécifique des produits finaux de glycosylation avancée , Acides gras monoinsaturés/pharmacologie , Produits terminaux de glycation avancée/métabolisme , Femelle , Animaux , Grossesse , Récepteur spécifique des produits finaux de glycosylation avancée/métabolisme , Rats , Muscles squelettiques/métabolisme , Muscles squelettiques/effets des médicaments et des substances chimiques , Espèces réactives de l'oxygène/métabolisme , Lignée cellulaire , Survie cellulaire/effets des médicaments et des substances chimiques , Souris , Compléments alimentaires , Protéines proto-oncogènes c-akt/métabolisme , Stress oxydatif/effets des médicaments et des substances chimiques , Insulinorésistance , Humains , Phosphorylation , Rat Sprague-Dawley , Grossesse chez les diabétiques/métabolisme , Grossesse chez les diabétiques/traitement médicamenteux , Mâle , Développement foetal/effets des médicaments et des substances chimiques
16.
Nutrients ; 16(12)2024 Jun 19.
Article de Anglais | MEDLINE | ID: mdl-38931289

RÉSUMÉ

Endothelial dysfunction decreases exercise limb blood flow (BF) and muscle oxygenation. Acute L-Citrulline supplementation (CIT) improves muscle tissue oxygen saturation index (TSI) and deoxygenated hemoglobin (HHb) during exercise. Although CIT improves endothelial function (flow-mediated dilation [FMD]) in hypertensive women, the impact of CIT on exercise BF and muscle oxygenation (TSI) and extraction (HHb) are unknown. We examined the effects of CIT (10 g/day) and a placebo for 4 weeks on blood pressure (BP), arterial vasodilation (FMD, BF, and vascular conductance [VC]), and forearm muscle oxygenation (TSI and HHb) at rest and during exercise in 22 hypertensive postmenopausal women. Compared to the placebo, CIT significantly (p < 0.05) increased FMD (Δ-0.7 ± 0.6% vs. Δ1.6 ± 0.7%) and reduced aortic systolic BP (Δ3 ± 5 vs. Δ-4 ± 6 mmHg) at rest and improved exercise BF (Δ17 ± 12 vs. Δ48 ± 16 mL/min), VC (Δ-21 ± 9 vs. Δ41 ± 14 mL/mmHg/min), TSI (Δ-0.84 ± 0.58% vs. Δ1.61 ± 0.46%), and HHb (Δ1.03 ± 0.69 vs. Δ-2.76 ± 0.77 µM). Exercise BF and VC were positively correlated with improved FMD and TSI during exercise (all p < 0.05). CIT improved exercise artery vasodilation and muscle oxygenation via increased endothelial function in hypertensive postmenopausal women.


Sujet(s)
Citrulline , Compléments alimentaires , Exercice physique , Force de la main , Hypertension artérielle , Muscles squelettiques , Post-ménopause , Débit sanguin régional , Vasodilatation , Humains , Femelle , Citrulline/pharmacologie , Adulte d'âge moyen , Hypertension artérielle/physiopathologie , Hypertension artérielle/traitement médicamenteux , Muscles squelettiques/métabolisme , Muscles squelettiques/effets des médicaments et des substances chimiques , Muscles squelettiques/vascularisation , Force de la main/physiologie , Vasodilatation/effets des médicaments et des substances chimiques , Débit sanguin régional/effets des médicaments et des substances chimiques , Sujet âgé , Exercice physique/physiologie , Pression sanguine/effets des médicaments et des substances chimiques , Oxygène/sang , Oxygène/métabolisme , Consommation d'oxygène/effets des médicaments et des substances chimiques , Méthode en double aveugle , Endothélium vasculaire/effets des médicaments et des substances chimiques
17.
Nutrients ; 16(12)2024 Jun 19.
Article de Anglais | MEDLINE | ID: mdl-38931310

RÉSUMÉ

BACKGROUND: Sarcopenia is an age-related condition characterized by progressive loss of muscle mass, strength, and function. The occurrence of sarcopenia has a huge impact on physical, psychological, and social health. Therefore, the prevention and treatment of sarcopenia is becoming an important public health issue. METHOD: 35 six-week-old male C57BL/6 mice were randomly divided into five groups, one of which served as a control group, while the rest of the groups were constructed as a model of sarcopenia by intraperitoneal injection of D-galactose. The intervention with lactoferrin, creatine, and their mixtures, respectively, was carried out through gavage for 8 weeks. Muscle function was assessed based on their endurance, hanging time, and grip strength. The muscle tissues were weighed to assess the changes in mass, and the muscle RNA was extracted for myogenic factor expression and transcriptome sequencing to speculate on the potential mechanism of action by GO and KEGG enrichment analysis. RESULT: The muscle mass (lean mass, GAS index), and muscle function (endurance, hanging time, and grip strength) decreased, and the size and structure of myofiber was smaller in the model group compared to the control group. The intervention with lactoferrin and creatine, either alone or combination, improved muscle mass and function, restored muscle tissue, and increased the expression of myogenic regulators. The combined group demonstrated the most significant improvement in these indexes. The RNA-seq results revealed enrichment in the longevity-regulated pathway, MAPK pathway, focal adhesion, and ECM-receptor interaction pathway in the intervention group. The intervention group may influence muscle function by affecting the proliferation, differentiation, senescence of skeletal muscle cell, and contraction of muscle fiber. The combined group also enriched the mTOR-S6K/4E-BPs signaling pathway, PI3K-Akt signaling pathway, and energy metabolism-related pathways, including Apelin signaling, insulin resistance pathway, and adipocytokine signaling pathway, which affect energy metabolism in muscle. CONCLUSIONS: Lactoferrin and creatine, either alone or in combination, were found to inhibit the progression of sarcopenia by influencing the number and cross-sectional area of muscle fibers and muscle protein synthesis. The combined intervention appears to exert a more significant effect on energy metabolism.


Sujet(s)
Créatine , Modèles animaux de maladie humaine , Lactoferrine , Souris de lignée C57BL , Muscles squelettiques , Sarcopénie , Animaux , Lactoferrine/pharmacologie , Mâle , Sarcopénie/traitement médicamenteux , Sarcopénie/métabolisme , Créatine/pharmacologie , Muscles squelettiques/effets des médicaments et des substances chimiques , Muscles squelettiques/métabolisme , Souris , Force musculaire/effets des médicaments et des substances chimiques , Transduction du signal/effets des médicaments et des substances chimiques
18.
Int J Mol Sci ; 25(12)2024 Jun 16.
Article de Anglais | MEDLINE | ID: mdl-38928337

RÉSUMÉ

3-(4-Hydroxy-3-methoxyphenyl)propionic acid (HMPA), also known as dihydroferulic acid, is a hydroxycinnamic acid derivative that can be derived from the microbial transformation of dietary polyphenols or naturally obtained from fermented foods. Although numerous studies have documented its antioxidant and anti-obesity effects, the effect of HMPA on muscle function remains unknown. This study investigated the effects of HMPA on muscle strength and exercise endurance capacity. Mice were orally administered low and high doses of HMPA for 14 days and subjected to grip force and treadmill exhaustion tests to evaluate muscle function. Our results showed that HMPA-administered groups significantly enhanced absolute grip strength (p = 0.0256) and relative grip strength (p = 0.0209), and low-dose HMPA decreased the plasma level of blood urea nitrogen after exercise (p = 0.0183), but HMPA did not affect endurance performance. Low-dose HMPA administration increased Myf5 expression in sedentary mice (p = 0.0106), suggesting that low-dose HMPA may promote muscle development. Additionally, HMPA improved hepatic glucose and lipid metabolism, and inhibited muscular lipid metabolism and protein catabolism, as indicated by changes in mRNA expression levels of related genes. These findings suggest that HMPA may be a promising dietary supplement for muscle health and performance.


Sujet(s)
Muscles squelettiques , Conditionnement physique d'animal , Animaux , Souris , Mâle , Muscles squelettiques/métabolisme , Muscles squelettiques/effets des médicaments et des substances chimiques , Acides coumariques/pharmacologie , Métabolisme lipidique/effets des médicaments et des substances chimiques , Propionates/pharmacologie , Force de la main , Force musculaire/effets des médicaments et des substances chimiques , Foie/métabolisme , Foie/effets des médicaments et des substances chimiques
19.
FASEB J ; 38(11): e23715, 2024 Jun 15.
Article de Anglais | MEDLINE | ID: mdl-38837260

RÉSUMÉ

Impaired intestinal permeability induces systemic inflammation and metabolic disturbance. The effect of a leaky gut on metabolism in skeletal muscle, a major nutrient consumer, remains unclear. In this study, we aimed to investigate the glucose metabolic function of the whole body and skeletal muscles in a mouse model of diet-induced intestinal barrier dysfunction. At Week 2, we observed higher intestinal permeability in mice fed a titanium dioxide (TiO2)-containing diet than that of mice fed a normal control diet. Subsequently, systemic glucose and insulin tolerance were found to be impaired. In the skeletal muscle, glucose uptake and phosphorylation levels in insulin signaling were lower in the TiO2 group than those in the control group. Additionally, the levels of pro-inflammatory factors were higher in TiO2-fed mice than those in the control group. We observed higher carboxymethyl-lysin (CML) levels in the plasma and intestines of TiO2-fed mice and lower insulin-dependent glucose uptake in CML-treated cultured myotubes than those in the controls. Finally, soluble dietary fiber supplementation improved glucose and insulin intolerance, suppressed plasma CML, and improved intestinal barrier function. These results suggest that an impaired intestinal barrier leads to systemic glucose intolerance, which is associated with glucose metabolism dysfunction in the skeletal muscles due to circulating CML derived from the intestine. This study highlights that the intestinal condition regulates muscle and systemic metabolic health.


Sujet(s)
Lysine , Muscles squelettiques , Titane , Animaux , Souris , Muscles squelettiques/métabolisme , Muscles squelettiques/effets des médicaments et des substances chimiques , Mâle , Lysine/analogues et dérivés , Lysine/métabolisme , Souris de lignée C57BL , Additifs alimentaires/pharmacologie , Insuline/sang , Insuline/métabolisme , Glucose/métabolisme , Intolérance au glucose/métabolisme , Muqueuse intestinale/métabolisme
20.
Sci Rep ; 14(1): 12826, 2024 06 04.
Article de Anglais | MEDLINE | ID: mdl-38834813

RÉSUMÉ

Lamin A/C gene (LMNA) mutations contribute to severe striated muscle laminopathies, affecting cardiac and skeletal muscles, with limited treatment options. In this study, we delve into the investigations of five distinct LMNA mutations, including three novel variants and two pathogenic variants identified in patients with muscular laminopathy. Our approach employs zebrafish models to comprehensively study these variants. Transgenic zebrafish expressing wild-type LMNA and each mutation undergo extensive morphological profiling, swimming behavior assessments, muscle endurance evaluations, heartbeat measurement, and histopathological analysis of skeletal muscles. Additionally, these models serve as platform for focused drug screening. We explore the transcriptomic landscape through qPCR and RNAseq to unveil altered gene expression profiles in muscle tissues. Larvae of LMNA(L35P), LMNA(E358K), and LMNA(R453W) transgenic fish exhibit reduced swim speed compared to LMNA(WT) measured by DanioVision. All LMNA transgenic adult fish exhibit reduced swim speed compared to LMNA(WT) in T-maze. Moreover, all LMNA transgenic adult fish, except LMNA(E358K), display weaker muscle endurance than LMNA(WT) measured by swimming tunnel. Histochemical staining reveals decreased fiber size in all LMNA mutations transgenic fish, excluding LMNA(WT) fish. Interestingly, LMNA(A539V) and LMNA(E358K) exhibited elevated heartbeats. We recognize potential limitations with transgene overexpression and conducted association calculations to explore its effects on zebrafish phenotypes. Our results suggest lamin A/C overexpression may not directly impact mutant phenotypes, such as impaired swim speed, increased heart rates, or decreased muscle fiber diameter. Utilizing LMNA zebrafish models for drug screening, we identify L-carnitine treatment rescuing muscle endurance in LMNA(L35P) and creatine treatment reversing muscle endurance in LMNA(R453W) zebrafish models. Creatine activates AMPK and mTOR pathways, improving muscle endurance and swim speed in LMNA(R453W) fish. Transcriptomic profiling reveals upstream regulators and affected genes contributing to motor dysfunction, cardiac anomalies, and ion flux dysregulation in LMNA mutant transgenic fish. These findings faithfully mimic clinical manifestations of muscular laminopathies, including dysmorphism, early mortality, decreased fiber size, and muscle dysfunction in zebrafish. Furthermore, our drug screening results suggest L-carnitine and creatine treatments as potential rescuers of muscle endurance in LMNA(L35P) and LMNA(R453W) zebrafish models. Our study offers valuable insights into the future development of potential treatments for LMNA-related muscular laminopathy.


Sujet(s)
Animal génétiquement modifié , Carnitine , Créatine , Lamine A , Muscles squelettiques , Mutation , Danio zébré , Animaux , Lamine A/génétique , Lamine A/métabolisme , Muscles squelettiques/métabolisme , Muscles squelettiques/anatomopathologie , Muscles squelettiques/effets des médicaments et des substances chimiques , Créatine/métabolisme , Carnitine/métabolisme , Modèles animaux de maladie humaine , Laminopathies/génétique , Laminopathies/métabolisme , Natation , Transcriptome , Humains
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...